Overview

A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia

Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The current study will explore the efficacy, safety and tolerability of 2 dose combinations of JM-010 to determine the optimal doses of each component to be studied in confirmatory clinical trials.
Phase:
Phase 2
Details
Lead Sponsor:
Contera Pharma
Collaborator:
Bukwang Pharmaceutical